Tumor Metabolic Pathway-related Enzyme Assay Service
Enzyme in Tumor Metabolism: Target for Effective Anti-cancer Therapy
Disorders in tumor lipid metabolism are closely linked to the occurrence, development, invasion, and metastasis of tumors. Targeting the abnormal metabolic pathways and related enzymes associated with cancer is crucial for effective anti-cancer therapy. A large range of novel medications may now selectively and effectively block tumor-relevant metabolic enzymes. Thus, understanding the drivers of metabolism is crucial for gaining insights into cancer susceptibility, identifying pathway intermediates and potential drug targets, and ultimately developing safe and effective cancer therapies.
Fig.1 Enzymes involved in metabolizing glucose are dysregulated in cancer cells.1
Our Tumor Metabolic Pathway-related Enzyme Assay Service
Enzymes play a crucial role in tumor metabolism pathways and have emerged as significant targets for anti-cancer therapy. Creative Biolabs offers a sensitive and robust tumor metabolic pathway-related enzyme assay service to aid in the development of cancer therapies. Based on well-established methods, we are continually improving our enzyme assay procedures, which are now characterized by increased sensitivity, excellent repeatability, and robust stability. Moreover, at Creative Biolabs, we can provide comprehensive customized services throughout the process to ensure the success of every customer's project and present you with high-quality outcomes in a short turnaround cycle.
In this service, we employ various methods to measure the enzyme activity:
-
Absorbance
-
Colorimetric-UV spectrophotometry
-
Fluorogenic
Our Tumor Metabolic Pathway-related Enzyme Assay Service can target diverse enzyme targets, including but not limited to the following:
Benefits for You
-
Wide selection of cell lines
We have a wide selection of expertly qualified and proven cell lines to choose from for global customers' projects.
-
High-sensitive, high-reproducibility
Our tumor metabolic pathway-related enzyme assay is consistently improved and honed in accordance with established methodologies, producing higher sensitivity, superior reproducibility, and strengthened stability.
We offer rigorous monitoring throughout the whole project operation process and timely handle any difficulties that emerge to guarantee the smooth operation of the entire project.
-
Top-ranking research team
Our research team consists of highly skilled experts. With their extensive experience and professional expertise, they can ensure an effortless execution of every project, from design to completion, thereby minimizing the occurrence of errors.
-
Comprehensive customized services
We customize the project's schedules to the specific requirements of every customer and provide comprehensive services from experiment designation to results presentation.
Data Support
Case 1: The table lists the most common and recent small molecules, compounds, anti-metabolites, and cytotoxins targeting tumor metabolic pathway-related enzymes. Many different novel medications have been developed that can selectively and efficiently block tumor-relevant metabolic enzymes. There are a number of considerations that need to be made before settling on a metabolic target for cancer treatment. It's possible that the physiological functions of certain metabolic enzymes in normal tissues also make them systemically toxic.
Fig.2 Cancer metabolomics-targeting compounds.2
Based on well-established methods, Creative Biolabs is continually improving our enzyme assay procedures, which are now characterized by increased sensitivity, excellent repeatability, and robust stability. If you want to know more about our tumor metabolic pathway-related enzyme assay service, please don't hesitate to get in touch with us.
References
-
Khan, Mohammad Aslam, et al. "Dysregulation of metabolic enzymes in tumor and stromal cells: Role in oncogenesis and therapeutic opportunities." Cancer Letters 473 (2020): 176-185.
-
Kumar, Rishabh, et al. "Metabolic pathways, enzymes, and metabolites: Opportunities in cancer therapy." Cancers 14.21 (2022): 5268.
For Research Use Only | Not For Clinical Use
Download our brochure